WO2002094286A1 - Inhibiteurs de metastases cancereuses contenant des derives d'acide phosphatidique carbacycliques - Google Patents
Inhibiteurs de metastases cancereuses contenant des derives d'acide phosphatidique carbacycliques Download PDFInfo
- Publication number
- WO2002094286A1 WO2002094286A1 PCT/JP2002/004839 JP0204839W WO02094286A1 WO 2002094286 A1 WO2002094286 A1 WO 2002094286A1 JP 0204839 W JP0204839 W JP 0204839W WO 02094286 A1 WO02094286 A1 WO 02094286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cpa
- group
- cells
- invasion
- cancer
- Prior art date
Links
- 239000002257 antimetastatic agent Substances 0.000 title claims abstract description 29
- PUPWWTUVIZOPTB-KTKRTIGZSA-N (2-hydroxy-2-oxo-1,2$l^{5}-oxaphospholan-4-yl)methyl (z)-octadec-9-enoate Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC1COP(O)(=O)C1 PUPWWTUVIZOPTB-KTKRTIGZSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 96
- 201000011510 cancer Diseases 0.000 claims abstract description 93
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- 150000001768 cations Chemical class 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 206010027476 Metastases Diseases 0.000 claims description 46
- 230000009401 metastasis Effects 0.000 claims description 39
- 230000004709 cell invasion Effects 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 230000008595 infiltration Effects 0.000 abstract description 41
- 238000001764 infiltration Methods 0.000 abstract description 41
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 abstract 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 107
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 69
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 66
- 230000009545 invasion Effects 0.000 description 64
- 230000000694 effects Effects 0.000 description 63
- 230000001394 metastastic effect Effects 0.000 description 61
- 206010061289 metastatic neoplasm Diseases 0.000 description 61
- 238000012360 testing method Methods 0.000 description 42
- -1 cyclic phosphatidic acid derivative Chemical class 0.000 description 33
- 239000000126 substance Substances 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 23
- 230000003834 intracellular effect Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 208000001382 Experimental Melanoma Diseases 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000009650 gentamicin protection assay Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000013210 hematogenous Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 210000005033 mesothelial cell Anatomy 0.000 description 7
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- QNYBOILAKBSWFG-JTQLQIEISA-N (2r)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-JTQLQIEISA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000003281 pleural cavity Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 101100194322 Caenorhabditis elegans rei-1 gene Proteins 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000003518 stress fiber Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QNYBOILAKBSWFG-UHFFFAOYSA-N 2-(phenylmethoxymethyl)oxirane Chemical compound C1OC1COCC1=CC=CC=C1 QNYBOILAKBSWFG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- JEFDYHWPYRIMCZ-UHFFFAOYSA-N 8-(3-methylbutyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCC(C)C)N2 JEFDYHWPYRIMCZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241001247986 Calotropis procera Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100112225 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cpa-1 gene Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000224486 Physarum polycephalum Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229910000147 aluminium phosphate Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical group CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000003856 jejunal cancer Diseases 0.000 description 1
- 201000009592 jejunal neoplasm Diseases 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical group C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000026517 ureter neoplasm Diseases 0.000 description 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Definitions
- the present invention relates to a cancer metastasis inhibitor comprising a fulva cyclic phosphatidic acid derivative as an active ingredient.
- Lysophosphatidic acid has the simplest structure among the phospholipids that compose the biological membrane, and is derived from phosphatidic acid (PA) to the sn -1 position or the 2nd position
- PA phosphatidic acid
- Figure 1 One of the fatty acids is desacylated.
- LPA phosphatidic acid
- Figure 1 One of the fatty acids is desacylated.
- LPA phosphatidic acid
- Figure 1 One of the fatty acids
- the percentage of LPA in total phospholipids is extremely low, less than 0.5%, and until the 1980s, it was simply not recognized as an intermediate or degradation product of phospholipid biosynthesis.
- various physiological activities of LPA have been shown (Moolenaar, WH: Exp. Cell Res. 253, 230-238 (1999)), and the existence of multiple receptors on the cell membrane has also been revealed (Guo Natl. Acad. Sci.
- LPA LPA is known to cause various effects depending on the cell type.
- promoting cell proliferation van Corven, EJ, et al., Cell 59, 45-54 (1989)
- suppressing cell death Umansky, SR, et al., Cell Death Diff. 4, 608-616 (1997)
- Rho one of the low molecular weight G proteins
- a monophasic myxoamoeba of the slime mold Physarum polycephalum found a fat-soluble substance that suppressed the activity of DM polymerase, a DNA replication enzyme in eukaryotic cells, and suppressed the growth of animal cultured cells. Isolated and purified
- cPA In mouse fibroblasts (NIH3T3), cPA has been found to increase intracellular cAMP levels within minutes. This phenomenon disappeared by preventing the rise of intracellular Ca 2+ concentration (Murakami-Murofushi, K., et al., Cell Struct. Funct. 18, 363-370 (1993)), and cPA was It is possible that Ca 2+ -dependent adulate cyclase is activated via the above receptor. Increased intracellular cAMP concentration has been shown to inhibit MAP kinase activation (Hordijk, PL, et al., J. Biol. Chem. 269, 3534-3538 (1994); and Howe, LR, et al. , J. Biol.
- cPA is considered to be easily taken into cells due to its structure.
- cPA by synthesizing cPA fluorescently labeled at the sn-1 position, adding it to cells, and observing its behavior, cPA is rapidly translocated into cells and localized in the cytoplasm and around the nucleus.
- cPA inhibits the activity of cdc25 phosphatase that regulates the cell cycle in vitro (Tetsuyuki Kobayashi and Kimiko Murofushi: Protein Nucleic Acid Enzyme 44, 1118-1125 (1999)). This suggests that cPA may inhibit cell proliferation by directly suppressing the activation of the cdk2 kinase complex in the cytoplasm without using the receptor on the cell membrane.
- both LPA and cPA induce the formation of stress fibers by intracellular actin molecules (Tetsuyuki Kobayashi and Miko Murofushi: Protein Nucleic Acid Enzyme 44, 1118-1125 (1999)).
- cPA like LPA, is thought to cause its effect by activating Rho through binding to cell membrane receptors.
- cPA exhibits strong suppressing activity (Mukai, M., others, Int. J. Cancer 81, 918-922 (1999)) 0
- Cancer metastasis is the most prominent symptom of tumor malignancy, and it is a complex process. Above all, invasion is a characteristic step, and cancer that has been released from the primary focus in vivo Cells invade the interstitium and blood vessels and are carried along the bloodstream, invading extravascular and further distant organs, where they proliferate and form metastatic foci.
- Akada and colleagues modeled the peritoneal invasion that occurred when rat ascites hepatoma cells (AH-130) were transplanted into the peritoneal cavity of a rat.
- AH-130 hepatoma cells
- cPA also inhibits Rho activity through activation of cAMP-dependent protein kinase A (A kinase) by increasing intracellular cAMP concentration.
- a kinase cAMP-dependent protein kinase A
- carboxylic acid phosphatidic acid induced It has not been reported whether the body has an inhibitory effect on the invasion of cancer cells. Disclosure of the invention
- An object of the present invention was to solve the problem of providing a novel cancer metastasis inhibitor by examining the inhibitory action of carboxycyclic phosphatidic acid derivatives on cancer cell invasion.
- the present inventors have described 11 cPA derivatives chemically synthesized by the method established by Kobayashi et al. (Kobayashi, S., et al., Tetrahedron Letters 34, 4047-4050 (1993)), as an in vitro invasion system.
- the effects on serum and LPA-dependent infiltration in rats were examined (Example 1 below).
- cPA derivatives showing 10 to 100 times stronger invasion-inhibiting activity than Pal-cPA were found, and their effects on LPA-independent invasion were examined (Example 2 below).
- the mechanism of action of the invasion-suppressing activity by the cPA derivative was examined (Example 3 below).
- the present inventors have demonstrated that a cyclic phosphatidic acid derivative has a cancer cell invasion inhibitory activity, and completed the present invention.
- R is a linear or branched alkyl group having 1 to 30 carbon atoms, a linear or branched alkenyl group having 2 to 30 carbon atoms, or a linear or branched alkyl group having 2 to 30 carbon atoms.
- Alkynyl groups, and these groups may contain a cycloalkane ring or an aromatic ring.
- M is a hydrogen atom or a counter cation.
- a cancer metastasis inhibitor comprising a compound represented by the formula (1) as an active ingredient:
- a cancer metastasis inhibitor which suppresses cancer metastasis by suppressing invasion of cancer cells.
- a method for suppressing cancer metastasis comprising administering a therapeutically effective amount of a compound represented by the above general formula (I) to mammals including humans.
- FIG. 1 is a diagram showing the structures of LPA, PHYLPA, and cPA.
- FIG. 2 is a diagram showing the structure of a chemically synthesized cPA derivative.
- FIG. 3 shows the in vitro invasion system.
- FIG. 4 shows the effect of cPA derivatives on FBS-induced invasion.
- FIG. 5 shows the effect of cPA derivatives on LPA-induced invasion.
- FIG. 6 is a diagram showing the pathway of chemical synthesis of Carba-cPA. The numbers in the figure refer to the embodiments.
- FIG. 7 shows the effect of carba-cPA on LPA-induced invasion.
- FIG. 8 is a diagram showing the effect of cPA on the proliferation of a single cell.
- FIG. 9 shows the effect of cPA on infiltration of HT-1080 cells.
- FIG. 10 shows the effect of the cAMP-elevating reagent on LPA-induced invasion.
- a reagent for increasing intracellular cAMP concentration was added to 1.5 ⁇ 10 5 cells / ml of thigh 1 cells in the presence of 25 ⁇ M LPA at the concentration shown in the figure, and in vitro infiltration was performed. The invasion-suppressing action of these was shown as a percentage (%) of the control.
- FIG. 11 shows the effect of cPA on intracellular cyclic AMP.
- the reaction was stopped after a certain period of time by adding 25 / zM cPA to one cell, and the intracellular cAMP concentration was measured.
- Figure 12 shows the change in body weight in each test group in an experiment in which the inhibitory effect of cyclic phosphatidic acid derivatives cPA-19 and cPA-20 on the lung metastasis of B16 melanoma using the B16 melanoma hematogenous lung metastasis model was examined. .
- Figure 13 shows the results of the number of metastatic nodules in the lung in an experiment in which the inhibitory effects of cyclic phosphatidic acid derivatives cPA-19 and cPA-20 on the lung metastasis of B16 melanoma using the B16 melanoma hematogenous lung metastasis model were examined.
- Fig. 14 shows the results of histopathological examination in an experiment in which the inhibitory effects of cyclic phosphatidic acid derivatives cPA-19 and cPA-20 on lung metastasis of B16 melanoma using a B16 melanoma hematogenous lung metastasis model were examined. Show. BEST MODE FOR CARRYING OUT THE INVENTION
- the cancer metastasis inhibitor of the present invention has a general formula (I): ⁇
- R is a linear or branched alkyl group having 1 to 30 carbon atoms, a linear or branched alkenyl group having 2 to 30 carbon atoms, or a linear or branched alkenyl group having 2 to 30 carbon atoms. These are branched alkynyl groups, and these H groups may contain a cycloalkane ring or an aromatic ring.
- M is a hydrogen atom or a cation.
- the compound represented by the formula (1) contains a conductor as an active ingredient.
- specific examples of the linear or branched alkyl group having 1 to 30 carbon atoms represented by the substituent R include a methyl group, an ethyl group, a propyl group, a butyl group and a pentyl group. , Hexyl, heptyl, octyl, nonyl, decyl, pentadecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, etc. Can be
- straight-chain or branched alkenyl group having 2 to 30 carbon atoms represented by the substituent R include, for example, an aryl group, a butyr group, an octyl group, a decenyl group, a dodecenyl group, and a hexadecatrenyl group.
- linear or branched alkynyl group having 2 to 30 carbon atoms represented by the substituent R For example, 8-decinyl group, 8-indesinyl group, 8-dodecinyl group, 8 monotridecinyl group, 8-tetradecynyl group, 8 ⁇ antadecinyl group, 8-hexadecynyl group, 8-heptadecynyl group, 8 —Octadecynyl group, 8— ⁇ f cosynyl group, 8-docosininole group, heptadine-1,8-diynyl group and the like.
- cycloalkane ring which may be contained in the above-mentioned alkyl group, alkenyl group or alkynyl group include, for example, a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cyclooctane ring and the like.
- the cycloalkane ring may contain one or more heteroatoms, and examples thereof include an oxylane ring, an oxetane ring, a tetrahydrofuran ring, and an N-methinoleprolysine ring.
- aromatic ring which may be contained in the above-mentioned alkyl group, alkenyl group or alkynyl group include, for example, a benzene ring, a naphthalene ring, a pyridine ring, a furan ring and a thiophene ring.
- substituent R is an alkyl group substituted by a cycloalkane ring
- specific examples include a cyclopropylmethyl group, a cyclohexylethyl group, and an 8,9-methanopentadecyl group.
- M in the cyclic phosphatidic acid (cPA) derivative represented by the general formula (I) is a hydrogen atom or a counter cation.
- M in the cyclic phosphatidic acid (cPA) derivative represented by the general formula (I) is a hydrogen atom or a counter cation.
- M is a counter cation include an alkali metal atom, an alkaline earth metal atom, and a substituted or unsubstituted ammonium group.
- the alkali metal atom include lithium, sodium and potassium
- examples of the alkaline earth metal atom include magnesium and potassium.
- the substituted ammonium group include a butylammonium group, a triethylammonium group, and a tetramethylammonium group.
- the obtained alcohol is reacted with excess pyridinium salt of p-toluenesulfonic acid in toluene at 80 ° C. to give a cyclized product (3).
- This cyclized product is subjected to hydrogenolysis using 20% Pd (0H) 2 -C under a hydrogen atmosphere to debenzylate (4).
- 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride as a condensing agent, it is reacted with a fatty acid to obtain a coupling product (5).
- the cyclic phosphonic acid (6) is obtained by regioselectively removing only the methyl group using bromotrimethylsilane as a nucleophile. This is transferred to a separating funnel using ether, and a small amount of a 0.02N aqueous sodium hydroxide solution is added dropwise to carry out a liquid separating operation to extract and purify the target compound as a sodium salt (7).
- the present invention relates to a novel cancer metastasis inhibitor.
- Cancer metastasis begins with the detachment of cancer cells from the primary focus, and involves multiple stages of rupture of extracellular matrix, invasion into blood vessels, invasion across the vascular endothelial cell layer, adhesion at distant organs, and proliferation. Take the process. Various factors are involved in these processes, and their inhibitors are attracting attention as new cancer metastasis inhibitors. Above all, invasion is the most characteristic step of the metastasis phenomenon, and it is highly likely that a superior anticancer agent will be developed from substances that suppress cancer cell invasion.
- the present invention provides a novel cancer metastasis inhibitor that can be used as a cancer cell invasion inhibitor.
- Cancer metastasis in the present invention means that cancer cells move and proliferate from one place to another organ, organ, etc., ie, cancer cells move to a site away from the primary focus to form cancer. It means both hematogenous and lymphatic.
- the type of cancer whose metastasis should be suppressed by the cancer metastasis inhibitor of the present invention is not particularly limited, and includes all benign tumors and malignant tumors.
- Specific examples of cancers that inhibit metastasis include malignant melanoma, malignant lymphoma, gastrointestinal cancer, lung cancer, esophageal cancer, stomach cancer, colon cancer, rectal cancer, colon cancer, ureteral tumor, gallbladder cancer, bile duct cancer, and biliary tract cancer , Breast, liver, victory, testicular, maxillary, tongue, lip, oral, pharyngeal, laryngeal, ovarian, uterine, prostate, thyroid, brain, liposarcoma, vascular Tumor, leukemia, polycythemia vera, neuroblastoma, retinoblastoma, bone marrow J3, cystoma, sarcoma, osteosarcoma, sarcoma, skin cancer, basal cell carcinoma, skin app
- breast cancer is in the lung, liver, bone, and lymph nodes
- gastric cancer is in the liver, lung, bone, adrenal gland
- colon cancer is the liver, lung, adrenal gland.
- metastasis occurs at a high rate.
- metastatic cancer include metastatic liver cancer, metastatic jejunal cancer, metastatic bone tumor, metastatic brain tumor, metastatic lung tumor, skin metastatic cancer, metastatic rib Jffi ulcer, metastatic ovarian cancer, and the like. Therefore, the cancer metastasis inhibitor of the present invention can be used to suppress such cancer metastasis, and is particularly useful as a postoperative metastasis inhibitor.
- the cancer metastasis inhibitor of the present invention is also a clinically effective cancer recurrence inhibitor, and is expected to prolong the patient's survival period and increase the survival rate.
- the cancer metastasis inhibitor of the present invention can be used in combination with known chemotherapy, surgical treatment, radiation therapy, hyperthermia, immunotherapy and the like.
- the cancer metastasis inhibitor of the present invention can further enhance the cancer metastasis inhibitory effect in combination with a known antitumor agent and Z or a cancer metastasis inhibitor.
- the cancer metastasis inhibitor of the present invention is provided in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable pharmaceutical additives and an active ingredient represented by the general formula (I). Is preferred.
- the cancer metastasis inhibitor of the present invention can be administered in various forms. It can be administered orally or parenterally (eg, intravenous, intramuscular, subcutaneous or intradermal injection, rectal administration, transmucosal administration) Etc.).
- Pharmaceutical compositions suitable for oral administration include, for example, tablets, granules, capsules, powders, solutions, suspensions, and syrups.
- Pharmaceutical compositions suitable for parenteral administration include: For example, injections, infusions, suppositories, transdermal absorption agents and the like can be mentioned, but the dosage form of the drug of the present invention is not limited to these.
- a sustained-release preparation can be prepared by a known technique.
- the kind of the pharmaceutical additive used for producing the drug of the present invention is not particularly limited, and can be appropriately selected by those skilled in the art.
- excipients, disintegrants or disintegrants, binders, lubricants, coatings, bases, dissolving or dissolution aids, dispersants, suspensions, emulsifiers, buffers, antioxidants, preservatives Agents, tonicity agents, PH regulators, solubilizers, stabilizers, and the like can be used, and the specific components used for these purposes are well known to those skilled in the art.
- compositions for oral administration include, for example, excipients such as pudose, lactose, D-mannitol, starch, and crystalline cellulose; carboxymethylcellulose, starch, or carboxymethylcellulose calcium Disintegrators or disintegration aids such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polybutylpyrrolidone, or gelatin; binders such as magnesium stearate or talc; hydroxypropylmethylcellulose; sucrose And coating agents such as polyethylene glycol or titanium oxide; bases such as petrolatum, liquid paraffin, polyethylene glycol, gelatin, kaolin, glycerin, purified water, and hard fat can be used.
- excipients such as pudose, lactose, D-mannitol, starch, and crystalline cellulose
- carboxymethylcellulose, starch, or carboxymethylcellulose calcium Disintegrators or disintegration aids such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polybutylpyrrolidone
- compositions for injection or infusion include distilled water for injection, physiological saline, propylene glycol, etc. Solubilizing agents or solubilizing agents that can constitute injections; tonicity agents such as glucose, sodium chloride, D-ditol, and glycerin; preparations such as pH regulators such as inorganic acids, organic acids, inorganic bases or organic bases Additives can be used.
- the agent of the present invention can be administered to mammals including humans.
- the dose of the drug of the present invention should be appropriately adjusted according to conditions such as the age, sex, weight, symptoms, and administration route of the patient.
- the amount is in the range of about 1,000 mg / kg, preferably in the range of about 10 / ig / kg to about 10 mg / kg.
- the above dose of the drug may be administered once a day, or may be administered in several divided doses (eg, about 2 to 4 doses).
- Example 1 Synthesis of cPA derivatives and their inhibition of cancer cell invasion
- ⁇ 1 cells a highly invasive clone of rat ascites hepatoma cells (AH-130), were established by Mukai et al. (Int. J. Cancer: 81, 918-922 (1999)), under conditions similar to those of mesothelial cells. Cultured under
- cPA and LPA were used in PBS containing 0.1% fatty acid free BSA (SIGMA), ice-cooled, sonicated, emulsified, and stored at 120 ° C.
- SIGMA fatty acid free BSA
- the medium containing 10% FBS, 12. was added 5 ⁇ M, 25 ⁇ cPA of M, 37 ° C, 5% C0 24 hours 2 conditions, the number of cells 72 hr cultured negation 1 cells, Force using a hemocytometer
- Human fibrosarcoma cells have been established by Mukai et al. (Int. J. Cancer: 81, 918-922 (1999)) and contain 1/100 volume of a non-essential amino acid solution (GIBCO BRL). ) in Eagle MEM1 (Nissui) supplemented with at Medumu plus 10% FBS, 37 ° (: , it was cultured under conditions of 5% C0 2.
- HT-1080 cells were collected by treatment with 0.05% trypsin, washed with serum-free medium, and subjected to the same assay as described in Chapter 1 in the absence of serum and LPA. Fixed and infiltrated cells were counted.
- HT- 1080 cells medium instead of the serum-free medium, and 20 hours incubation under the conditions of 37 ° C, 5% C0 2 . This medium was collected, and the supernatant obtained by centrifugation was used as a culture supernatant. Using this supernatant, cells once washed were suspended, and infiltration was performed in the same manner as in paragraph 043.
- HT-1080 cells infiltrate serum / LPA-independently in an in vitro invasion system. This phenomenon has also been found to be suppressed by Pal-cPA
- Table 1 shows the results of in vitro infiltration assay, in which 1.5 ⁇ 10 5 cells / ml of concealed 1 cells were suspended in serum-free culture supernatant of HT-1080 cells.
- Forskolin (Wako), which directly activates adenylate cyclase, which is a cAMP synthase, and cholera toxin (CTX, Cholera Toxin, which prevents inactivation of G protein (G s ), which activates adenylate cyclase ) (GIBCO BRL), an isobutyl methylxanthin (IBMX, 3) that inhibits phosphogesterase, a Bt 2 cAMP (nacalai tesque) N cAMP degrading enzyme that is membrane permeable and enters cells and acts like cAMP.
- -isobutyl-l-methylxanthine) (SIGMA) to the in vitro infiltration assay system, The effect on M1 cell invasion was examined in the presence of 25 ⁇ LPA.
- Increased intracellular cAMP concentration is known to inhibit the activity of Rho, one of low molecular weight G proteins, through activation of cAMP-dependent protein kinase A
- the invasion of cancer cells was suppressed by any of the reagents.
- Forskolin as a positive control, the change in intracellular cAMP concentration due to the addition of carba-cPA was examined, and its involvement in invasion suppression activity was examined.
- Example 1 in vitro invasion was performed using various cPA derivatives.
- cPA derivatives including Pal-cPA, which showed infiltration suppression exceeding 50% when 25 ⁇ M was added (Fig. 5).
- CPA-12 with EPA at sn-1 that suppressed serum-induced invasion by about 70% did not inhibit LPA-induced invasion. This suggested that serum may contain infiltration promoting substances other than LPA.
- Example 2 focusing on this carba-cPA, the effect of carba-cPA on the invasion was examined using cancer cells that do not require serum and LPA for invasion. As shown in FIG. 9, even in LPA-independent invasion, the same strong invasion-suppressing activity by carba-cPA as in native cPA was observed.
- Example 3 the mechanism of action of carba-cPA to suppress invasion was analyzed.
- LPA promotes invasion through activation of Rho, one of the low molecular weight proteins.
- Additional of Pal-cPA increases intracellular cAMP concentration and further suppresses Rho activity Therefore, we considered the possibility that carba-cPA also increased the intracellular cAMP concentration and, as a result, suppressed invasion, and measured the intracellular cAMP concentration (Fig. 11).
- the increase in cAMP concentration due to the positive control Forskolin was measured, the increase in cAMP concentration due to Pal-cPA could not be confirmed.
- no change in cAMP concentration was observed by carba-Pal-cPA.
- Example 4 Inhibitory effect of cyclic phosphatidic acid derivatives cPA-19 and cPA-20 on lung metastasis of B16 melanoma using B16 melanoma hematogenous lung metastasis model
- CPA-19 and cPA-20 were used as test substances.
- As a medium it was prepared by dissolving Albumin, Bovine Less Essentially Fatty Acid Free] (BSA, Lot No. 89H7604, Sigma chemical company) with PBS (pH 7.2) free from Ca 2+ and Mg 2+ . lw / v% BSA / PBS was used. After the preparation, the solution was sterilized by filtration through a filter (0.22) 11, Millipore). Prepared before use. CPA-5 was used as a positive control.
- the required amount of the medium was added to the test substance or positive control substance, and dissolved by sonication to prepare a 0.16 mg / mL solution.
- the 0.16 mg / mL solution was diluted with the vehicle to prepare 0.08 and 0.02 mg / mL solutions. All mixed substances were prepared at the time of use.
- a mouse was purchased from Nippon Charls River Co., Ltd.
- the strain was C57BL / 6NCrj, the sex was female, the number of animals received was 60, the age at the time of arrival was 4 weeks, and the weight range was 10.2 to 14.0 g.
- the environmental conditions of the test system are as follows
- Feed Solid feed CRF-1 (Oriental Yeast Kogyo Co., Ltd.) was autoclaved and fed freely.
- Drinking water Well water supplemented with sodium hypochlorite (residual chlorine concentration: about 2 ppm) was freely ingested through a water bottle.
- Bedding White flakes (Japan (Charles River Co., Ltd.) was used after autoclaving.
- Rearing cage and replacement frequency Polycarbonate cages (W215 XH140 XD320 mm) sterilized by autoclaving were replaced twice a week at the same time as the bedding. Number of caged animals: 5 animals per cage during the quarantine acclimation period, and 3 animals per cage during the test period.
- Cleaning and disinfection The breeding room was cleaned daily and the floor was cleaned with a disinfectant solution.
- Mouse malignant melanoma B16-F0 was used as tumor cells. Purchased from Dainippon Pharmaceutical Co., Ltd.
- a cell suspension was prepared in the same manner as in the subculture method. That is, after washing the cells with a phosphate buffer [PBS (-)] containing V 2 containing Ca 2+ and Mg 2+ , the collected cells are suspended in 10 mL PBS (-) to prepare a cell suspension. did. The number of cells in the cell suspension was counted and defined as the total number of cells. 50 ⁇ L of the cell suspension, 100 ⁇ L of 0.4% trypan blue solution and 100 ⁇ L of PBS ( ⁇ ) were mixed, and the number of viable cells was counted. Cell viability was calculated from the number of living cells and the total number of cells. Based on these results, the number of viable cells was adjusted to 1 ⁇ 10 7 cells / mL, and a tumor cell suspension for transplantation was prepared.
- PBS (-) phosphate buffer
- the vehicle, the test substance or the positive control substance was mixed with the B16-F0 cell suspension at a ratio of 1: 1 and the mixed liquid was administered into the tail vein.
- the number of transplanted cells was 5 ⁇ 10 5 cells / body.
- the dose of the test substance was 0.001, 0.004 or 0.008 mg / body, and the dose of the positive control substance was 0.008 mg / body.
- the observation period was up to 14 days after the administration of the test substance. During this time, we checked daily life and death and observed the general condition. Body weight was measured twice a week.
- the specimens were embedded in paraffin and thin sections were prepared. This After preparing hematoxylin and eosin-stained specimens from these sections, the number of metastatic foci was measured at certain sites on the left lobe and posterior lobe, and classified according to size. Based on the objective lens diameter (0.65 thigh), which is 40 times longer than the major axis of the transfer site, the size should be smaller than 0.65 thigh and smaller than 0.65 mm or more and less than 1.30 thigh. Classified as In addition, the degree of lymphocyte infiltration into the metastasis was qualitatively confirmed.
- the representative value of each test group was expressed as the average soil standard deviation (mean soil S.D.).
- the mean difference test was performed using the Dunnett's multiple comparison test (Dunnett's multiple comparison test) for the number of metastatic nodules between the vehicle group and the cPA-19 group, and between the vehicle group and the cPA-20 group. Tests were performed between the vehicle group and the cPA-5 group by Student's T-test. The number of metastatic foci was tested by the Wilcoxon test using the vehicle group as a control. The number of individuals with metastatic nodules or metastases was tested by Fisher's extract probability test (Fisher's extractability test) using the vehicle group as a control. Significance levels were 1 and 5%.
- the values were 16.5 ⁇ 1.0, 16.7 ⁇ 0.6 and 16.8 ⁇ 0.5, respectively.
- the values were 16.8 ⁇ 0.4, 16.9 ⁇ 0.7 and 17.0 ⁇ 0.9 g, respectively.
- the weight was 17.0 ⁇ 0.8 g.
- the dose was 17.3 ⁇ 1.2 g in the vehicle group.
- the body weight at each measurement was compared with the body weight on the day of test substance administration.On the 4th day after test substance administration, the vehicle group, 0.001 of cPA-19 and 0.008 mg / body, and 0.001 mg of cPA-20 In the mg / body group and cPA-5, transient weight loss was observed. Lung metastasis nodules ( Figure 13 and Table 4)
- mice (average S.D.)
- the number of individuals with metastatic nodules was 6 in the vehicle group. There were 6, 6, and 0 patients in the 0.001 mg, 0.004 mg and 0.008 mg / body dose groups of cPA-19, respectively. There were 6, 2 and 1 cases in the 0.001, 0.004 and 0.008 mg / body dose groups of cPA-20, respectively. There were 6 cases in the cPA-5 group. The number of individuals with metastatic nodules was significantly reduced in the 0.008 mg / body cPA-19 administration group and the 0.000 and 0.008 mg / body cPA-20 administration groups as compared to the vehicle group. The number of metastatic nodules was 49 ⁇ 20 (minimum-maximum: 28-84, same hereafter) in the vehicle group.
- Table 5 shows the results of the autopsy.
- metastatic nodules were observed in the pleural cavity (1 case), in the abdominal cavity, in the spleen (5 cases), in the ovary (2 cases), and in the fat tissue (2 cases).
- intrathoracic (1 case) intraperitoneal spleen (1 case), ovary (2 cases), adrenal gland (1 case), kidney (2 cases) and adipose tissue Metastasis nodules were observed in 1 case.
- No metastatic nodules were found in the pleural cavity in the 0.004 mg / body cPA-19 group, and metastatic nodules were found in the abdominal cavity in the spleen (1 case), adrenal gland (1 case) and adipose tissue (1 case) was.
- mice (mg / body) Number of mice Small size 2) Large size 2 )
- the number of individuals with metastatic foci was 6 in the vehicle group. There were 6, 2, and 0 subjects in the 0.001, 0.004, and 0.008 mg / body dose groups of cPA-19, respectively. There were 4, 1, and 0 cases in the 0.001 mg, 0.004 mg and 0.008 mg / body administration groups of cPA-20, respectively. There were 5 cases in the cPA-5 group. The number of individuals with metastatic foci was significantly greater in the 0.004 and 0.008 mg / body cPA-19 groups and in the 0.004 and 0.008 mg / body cPA-20 groups than in the vehicle group. Diminished.
- the number of lung metastases was 1.3 ⁇ 1.5 for small metastases and 1.3 ⁇ 1.0 for large metastases in the vehicle group, for a total of 2.7 ⁇ 2.4 Met.
- the group given cPA-19 at 0.001 mg / body 3.0 ⁇ 1.3 small metastatic foci and 0.7 ⁇ 0.8 large metastatic foci, for a total of 3.7 ⁇ 1.8.
- the group administered with cPA-19 at 0.004 mg / body there were 0.3 ⁇ 0.5 small metastatic foci and no large metastatic foci were observed. No metastatic foci were observed in the group administered with cPA-19 at 0.008 mg / body.
- Lymphocyte infiltration into metastatic lesions was observed in 1 of 6 patients in the vehicle group.
- lymphocytes were infiltrated into metastatic lesions in 1 of 6 patients, but not in the 2 patients in the 0.004 mg / body group.
- lymphocyte infiltration into metastatic lesions was observed in 1 out of 4 cases, and was not observed in 1 case in the 0.004 mg / body administration group.
- cPA-5 group 2 out of 5 patients Lymphocytes infiltrating were observed. No difference was observed in the degree of lymphocyte infiltration into metastatic foci in each test group.
- Hematogenous metastasis one of the major pathways of cancer metastasis, begins with the detachment of cancer cells from the primary focus and infiltration of surrounding tissues, invading lymphatic vessels and blood vessels, and in the capillary bed of various organs. It is composed of complex reactive remplis, from adhesion to the formation of metastatic foci by proliferation at distant sites.
- the B16 melanoma hematogenous lung metastasis model used in this experiment is a moore that can examine the process after cancer cells that have released their primary focus have entered the vasculature (Poste G. and Fidler IJ: The pathogenesis of Cancer metastasis.
- Lysophosphatidic acid is one of the lysophospholipid mediators (Tetsuyuki Kobayashi, Kimiko Murofushi: Existence, metabolism and physiological function of lysophosphatidic acid and cyclic phosphatidic acid as lysophospholipid mediators, protein nucleic acid enzyme 44: 1118- 1126 (1999)), which is known to strongly induce invasion in in vitro invasion experiments (Matsuko Mukai, Hitoshi Akito): Induction of cancer cell invasion by lysophosphatidic acid and suppression of invasion by cyclic phosphatidic acid. Protein nucleic acid enzyme 44:
- Cancer metastasis is the most prominent phenomenon that indicates the malignancy of Jffi ulcers, and is established through a complex process. Above all, the invasion of cancer cells is a characteristic stage.
- the present invention has revealed that carba-cPA has a strong invasion-inhibiting activity, and it has become possible to provide a novel cancer metastasis inhibitor. Use of the cancer metastasis inhibitor of the present invention greatly contributes to cancer treatment.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02771731A EP1402894B1 (en) | 2001-05-21 | 2002-05-20 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
US10/477,210 US20040214799A1 (en) | 2001-05-21 | 2002-05-20 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
JP2002591003A JP4163007B2 (ja) | 2001-05-21 | 2002-05-20 | カルバ環状ホスファチジン酸誘導体を含む癌転移抑制剤 |
DE60224276T DE60224276T2 (de) | 2001-05-21 | 2002-05-20 | Krebsmetastasen-hemmer mit carbacyclischen phosphatidinsäurederivaten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-150685 | 2001-05-21 | ||
JP2001150685 | 2001-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002094286A1 true WO2002094286A1 (fr) | 2002-11-28 |
Family
ID=18995665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004839 WO2002094286A1 (fr) | 2001-05-21 | 2002-05-20 | Inhibiteurs de metastases cancereuses contenant des derives d'acide phosphatidique carbacycliques |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040214799A1 (ja) |
EP (1) | EP1402894B1 (ja) |
JP (1) | JP4163007B2 (ja) |
AT (1) | ATE381934T1 (ja) |
DE (1) | DE60224276T2 (ja) |
WO (1) | WO2002094286A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004010582A (ja) * | 2002-06-11 | 2004-01-15 | Gencom Co | カルバ環状ホスファチジン酸誘導体 |
WO2008081580A1 (ja) | 2006-12-28 | 2008-07-10 | Ochanomizu University | 環状ホスファチジン酸誘導体を含む鎮痛剤 |
WO2013069404A1 (ja) | 2011-11-11 | 2013-05-16 | Sansho株式会社 | 関節症治療剤 |
WO2014115885A1 (ja) | 2013-01-28 | 2014-07-31 | 国立大学法人お茶の水女子大学 | 脱髄疾患治療薬 |
WO2021100847A1 (ja) | 2019-11-22 | 2021-05-27 | 国立大学法人お茶の水女子大学 | カルバリゾホスファチジン酸 |
WO2022114058A1 (ja) | 2020-11-26 | 2022-06-02 | Sansho株式会社 | 肺線維症治療剤 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4836345B2 (ja) * | 2001-04-13 | 2011-12-14 | きみ子 室伏 | 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤 |
JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び/又は生存の促進のための薬剤 |
CA2672513C (en) * | 2007-02-15 | 2010-05-25 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
EP2136844B1 (en) | 2007-03-20 | 2018-10-31 | SCF Pharma Inc. | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
WO2016024605A1 (ja) | 2014-08-12 | 2016-02-18 | 大塚化学株式会社 | 環状ホスホン酸ナトリウム塩の結晶及びその製造方法 |
EP3749297A4 (en) | 2018-02-07 | 2021-04-14 | SCF Pharma Inc. | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, CORRESPONDING COMPOSITIONS, METHODS AND USES |
CN112384212A (zh) | 2018-05-03 | 2021-02-19 | Scf制药股份有限公司 | 多不饱和脂肪酸单甘油酯、其组合物、方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06228169A (ja) * | 1993-02-05 | 1994-08-16 | Sagami Chem Res Center | 1−o−アシルグリセロール2,3−ホスフェートの製造法 |
JPH0925235A (ja) * | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | 1−o−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
WO2000057864A2 (en) * | 1999-03-25 | 2000-10-05 | Yeda Research And Development Co. Ltd. | Cyclic glycerophosphates and analogs thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US811786A (en) * | 1904-03-15 | 1906-02-06 | Franklin P Miller | Tool-holder. |
US936793A (en) * | 1908-12-22 | 1909-10-12 | Charles R Middleton | Cutting-tool for planers, lathes, &c. |
US2799079A (en) * | 1955-04-29 | 1957-07-16 | Modern Corp | Cutting tools |
US3124864A (en) * | 1960-10-05 | 1964-03-17 | frommelt etal | |
US3500522A (en) * | 1967-03-01 | 1970-03-17 | Carmet Co | Cutoff tool holder |
US3534457A (en) * | 1968-05-02 | 1970-10-20 | Willey S Carbide Tool Co | Cutting insert mounting assembly |
US3646649A (en) * | 1969-09-05 | 1972-03-07 | Kennametal Inc | Grooving and cutoff tool |
US3693224A (en) * | 1971-03-08 | 1972-09-26 | Fansteel Inc | Grooving tool |
US3959861A (en) * | 1972-04-28 | 1976-06-01 | Wlajko Mihic | Clamping arrangement for a cutting tool |
SE393759B (sv) * | 1974-04-08 | 1977-05-23 | Wlajko M | Anordning vid skerhallare |
SE392409B (sv) * | 1974-10-16 | 1977-03-28 | Seco Tools Ab | Skerverktyg |
FR2332090A1 (fr) * | 1975-11-21 | 1977-06-17 | Plansee Metallwerk | Porte-outil, notamment pour tours a copier |
IL58378A (en) * | 1979-10-03 | 1981-10-30 | Iscar Ltd | Tool holder for a single cutting insert |
US4321846A (en) * | 1980-04-18 | 1982-03-30 | The Gillette Company | Tool holder |
US4552491A (en) * | 1980-06-23 | 1985-11-12 | United Technologies Corporation | Cutting tool having cylindrical ceramic insert |
IL61368A (en) * | 1980-10-29 | 1984-05-31 | Iscar Ltd | Holder assembly for tools such as apertured cutting inserts |
DE3201508C1 (de) * | 1982-01-20 | 1988-07-07 | Mapal Fabrik für Präzisionswerkzeuge Dr.Kress KG, 7080 Aalen | Einmesser-Reibahle |
JP2701514B2 (ja) * | 1989-06-15 | 1998-01-21 | 三菱マテリアル株式会社 | スローアウエイチップのクランプ機構 |
DE9317533U1 (de) * | 1993-11-16 | 1994-02-10 | Krupp Widia Gmbh | Halter für spanabhebende Werkzeugeinsätze |
JPH07258278A (ja) * | 1994-03-18 | 1995-10-09 | Sagami Chem Res Center | 1−O−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするDNAポリメラーゼαの阻害剤 |
SE509362C2 (sv) * | 1994-03-18 | 1999-01-18 | Sandvik Ab | Diamantbelagd kropp |
SE508666C2 (sv) * | 1994-05-27 | 1998-10-26 | Sandvik Ab | Skärhållare för vändskärsplattor |
SE513952C2 (sv) * | 1998-05-29 | 2000-12-04 | Seco Tools Ab | Verktyg för skärande bearbetning |
US6150345A (en) * | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
SE519123C2 (sv) * | 1998-12-22 | 2003-01-14 | Seco Tools Ab | Skär och verktyg för skärande bearbetning samt metod för montering av skär i detta |
-
2002
- 2002-05-20 AT AT02771731T patent/ATE381934T1/de not_active IP Right Cessation
- 2002-05-20 JP JP2002591003A patent/JP4163007B2/ja not_active Expired - Fee Related
- 2002-05-20 WO PCT/JP2002/004839 patent/WO2002094286A1/ja active IP Right Grant
- 2002-05-20 US US10/477,210 patent/US20040214799A1/en not_active Abandoned
- 2002-05-20 EP EP02771731A patent/EP1402894B1/en not_active Expired - Lifetime
- 2002-05-20 DE DE60224276T patent/DE60224276T2/de not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06228169A (ja) * | 1993-02-05 | 1994-08-16 | Sagami Chem Res Center | 1−o−アシルグリセロール2,3−ホスフェートの製造法 |
JPH0925235A (ja) * | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | 1−o−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
WO2000057864A2 (en) * | 1999-03-25 | 2000-10-05 | Yeda Research And Development Co. Ltd. | Cyclic glycerophosphates and analogs thereof |
Non-Patent Citations (4)
Title |
---|
BESTMANN, H.J. ET AL.: "Phosphine alkylenes. 50. On the structure of 2,2,2,-triphenyl-1,2 lambda 5-oxaphospholanes", CHEMICAL BER., vol. 125, no. 1, 1992, pages 225 - 229, XP002955809 * |
DATABASE CAPLUS [online] 1986, WROBLEWSKI A.E., XP002957312, Database accession no. 1986:591524 * |
WROBLEWSKI, A.E., Z. NATURFORSCH., vol. 41B, no. 6, 1986, pages 791 - 792 * |
YOKOMATSU,T. ET AL.: "Electrophilic heteroatom cyclization of omega-alkenylphosphonic acid half esters giving cyclic phosphonates (phostones)", HETEROCYCLES, vol. 46, 1997, pages 463 - 472, XP002955808 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004010582A (ja) * | 2002-06-11 | 2004-01-15 | Gencom Co | カルバ環状ホスファチジン酸誘導体 |
US7550449B2 (en) | 2002-06-11 | 2009-06-23 | Kimiko Murofushi | Carba cyclic phosphatidic acid derivative |
WO2008081580A1 (ja) | 2006-12-28 | 2008-07-10 | Ochanomizu University | 環状ホスファチジン酸誘導体を含む鎮痛剤 |
US8017597B2 (en) | 2006-12-28 | 2011-09-13 | Ochanomizu University | Analgesic agent comprising cyclic phosphatidic acid derivative |
WO2013069404A1 (ja) | 2011-11-11 | 2013-05-16 | Sansho株式会社 | 関節症治療剤 |
RU2646457C2 (ru) * | 2011-11-11 | 2018-03-05 | Сансо Ко. Лтд. | Терапевтическое средство при артрозе |
WO2014115885A1 (ja) | 2013-01-28 | 2014-07-31 | 国立大学法人お茶の水女子大学 | 脱髄疾患治療薬 |
US10413559B2 (en) | 2013-01-28 | 2019-09-17 | Ochanomizu University | Method for treating demyelinating disease |
WO2021100847A1 (ja) | 2019-11-22 | 2021-05-27 | 国立大学法人お茶の水女子大学 | カルバリゾホスファチジン酸 |
WO2022114058A1 (ja) | 2020-11-26 | 2022-06-02 | Sansho株式会社 | 肺線維症治療剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4163007B2 (ja) | 2008-10-08 |
DE60224276T2 (de) | 2008-12-18 |
DE60224276D1 (de) | 2008-02-07 |
JPWO2002094286A1 (ja) | 2004-09-02 |
US20040214799A1 (en) | 2004-10-28 |
EP1402894A4 (en) | 2005-07-27 |
EP1402894B1 (en) | 2007-12-26 |
ATE381934T1 (de) | 2008-01-15 |
EP1402894A1 (en) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002094286A1 (fr) | Inhibiteurs de metastases cancereuses contenant des derives d'acide phosphatidique carbacycliques | |
KR100394157B1 (ko) | 아테롬성동맥경화증및기타심혈관질환및염증질환의치료방법 | |
AU2007246023B2 (en) | Use of compounds of the formula A-R-X or their pharmaceutically acceptable salts for producing a pharmaceutical preparation | |
Uchiyama et al. | Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid | |
JP2002514160A (ja) | Naaladアーゼ阻害剤 | |
KR101309538B1 (ko) | 엑콜 화합물을 함유하는 암 줄기세포 성장 억제용 조성물 | |
CA2522980A1 (en) | Water soluble wortmannin derivatives | |
KR20130004770A (ko) | 암 줄기세포 성장 억제용 조성물 | |
US7550449B2 (en) | Carba cyclic phosphatidic acid derivative | |
JP6706799B2 (ja) | 新規ビスホスホン酸誘導体及びその用途 | |
CN109152750A (zh) | 用于增殖性疾病的组合疗法 | |
JP6007264B2 (ja) | 脱髄疾患治療薬 | |
CN109963568A (zh) | 由铂基化合物进行免疫记忆诱导 | |
US20100028417A1 (en) | Use of substituted glycerin derivatives for producing a pharmaceutical preparation | |
Li et al. | A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs | |
JP5283962B2 (ja) | 医薬組成物 | |
US20230381083A1 (en) | Phytic Acid Ester Derivative | |
EP1299400B1 (en) | Novel cytotoxic compounds and their use | |
WO2008074572A1 (en) | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies | |
KR101478543B1 (ko) | 백합나무 수피 추출물을 함유하는 만성 골수성 백혈병 치료용 의약 조성물 | |
JP4963547B2 (ja) | オキソリン化合物を有効成分とする医薬 | |
JP2007106730A (ja) | Rantes誘導阻害薬 | |
WO2014010742A1 (ja) | モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物 | |
Wiemer | Inhibition of geranylgeranyl diphosphate synthase by isoprenoid bisphosphonates | |
KR20160036490A (ko) | 중쇄 지방산을 포함하는 암치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002591003 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002771731 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002771731 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10477210 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002771731 Country of ref document: EP |